HARMONY aims to assemble, assess, connect, and analyze heterogeneous data sources involving HM patients to define sets of outcome indicators by applying Big Data techniques that can be used for decision-making by key healthcare stakeholders. In addition, HARMONY will establish a system to foster rapid decision-making in the interests of better therapy access and care for patients. This shared goal is the leading force behind the entire consortium, and everyone involved has pledged to use their combined know-how and extensive access to the relevant existing networks, data and structures to ensure HARMONY’s success.

HARMONY-Talks: Anthony Moorman August 2018

Professor Anthony Moorman is leading the Pediatric Hematologic Malignancies Group. Pediatric Malignancies are the second leading cause of mortality in children in developed countries and hematologic malignancies (HMs) account for 40% of pediatric malignancies. Typical symptoms of pediatric HMs are fatigue and frequent infections. Acute lymphoblastic leukemia (ALL) is the most common HM in children; the other HMs that are studied in HARMONY are rare in children.